Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers.
Journal: Molecules (Basel, Switzerland)
Published: May 05, 2023
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 01, 2021
Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling.
Journal: Frontiers in pharmacology
Published: October 28, 2021
Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: July 27, 2021
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.
Journal: Molecular cancer therapeutics
Published: May 05, 2021
Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
Journal: Cancer chemotherapy and pharmacology
Published: April 15, 2021
Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
Journal: Molecules (Basel, Switzerland)
Published: September 20, 2020
Development of a Genomic Data Flow Framework: Results of a Survey Administered to NIH-NHGRI IGNITE and eMERGE Consortia Participants.
Journal: AMIA ... Annual Symposium proceedings. AMIA Symposium
Published: April 21, 2020
Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors.
Journal: Molecules (Basel, Switzerland)
Published: June 20, 2019
Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.
Journal: Cancer biology & therapy
Published: May 28, 2019
Last Updated: 09/26/2026